Risk of Kidney Failure in Patients with Systemic Sclerosis: a Nationwide Population-based Study

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2023 Nov 9

PMID 37945288

Authors

Oh Chan Kwon

Kyungdo Han

Min-Chan Park

Affiliations

Soon will be listed here.

Abstract

Objective: Data from a decade ago have shown that patients with systemic sclerosis (SSc) have a higher risk of kidney failure than the general population. However, as the incidence of kidney failure due to SSc has been declining, the comparative risk of kidney failure between patients with SSc and the general population could have changed over time. We investigated the risk of kidney failure in patients with SSc compared with the general population, up to more recent years.

Methods: This was a nationwide population-based study using the Korean National Health Insurance Service database. Patients with claims data for SSc between 2010 and 2017 (n=2591) and 1:5 age-matched and sex-matched controls (n=12 955) were selected. The index date was the earliest date of claim for SSc between 2010 and 2017. The follow-up duration was from the index date to 2019. The adjusted HRs (aHRs) and 95% CI for kidney failure were estimated using multivariable Cox proportional hazard models.

Results: Over 5.2±2.6 years, the incidence rates of kidney failure in patients with SSc and controls were 2.88 and 0.35 per 1000 person-years, respectively. Patients with SSc had a significantly higher risk of kidney failure than controls (aHR=7.244, 95% CI=4.256 to 12.329). The effect size was larger in patients diagnosed with SSc between 2014 and 2017 (aHR=9.754, 95% CI=3.254 to 29.235) than in those diagnosed before 2010 (aHR=6.568, 95% CI=2.711 to 15.571) or between 2010 and 2013 (aHR=6.553, 95% CI=2.721 to 15.781).

Conclusion: The risk of kidney failure remains higher in patients with SSc than in the general population.

References

Hsu C, McCulloch C, Darbinian J, Go A, Iribarren C . Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005; 165(8):923-8. DOI: 10.1001/archinte.165.8.923. View

Hsu C, McCulloch C, Iribarren C, Darbinian J, Go A . Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006; 144(1):21-8. DOI: 10.7326/0003-4819-144-1-200601030-00006. View

Sexton D, Reule S, Foley R . End-Stage Kidney Disease From Scleroderma in the United States, 1996 to 2012. Kidney Int Rep. 2018; 3(1):148-154. PMC: 5762953. DOI: 10.1016/j.ekir.2017.09.003. View

Hsu C, Iribarren C, McCulloch C, Darbinian J, Go A . Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med. 2009; 169(4):342-50. PMC: 2727643. DOI: 10.1001/archinternmed.2008.605. View

Bose N, Chiesa-Vottero A, Chatterjee S . Scleroderma renal crisis. Semin Arthritis Rheum. 2015; 44(6):687-94. DOI: 10.1016/j.semarthrit.2014.12.001. View

Kim M, Han K, Koh E, Kim H, Kwon H, Park Y . Variability in Total Cholesterol Is Associated With the Risk of End-Stage Renal Disease: A Nationwide Population-Based Study. Arterioscler Thromb Vasc Biol. 2017; 37(10):1963-1970. PMC: 6349220. DOI: 10.1161/ATVBAHA.117.309803. View

Scheen M, Dominati A, Olivier V, Nasr S, de Seigneux S, Mekinian A . Renal involvement in systemic sclerosis. Autoimmun Rev. 2023; 22(6):103330. DOI: 10.1016/j.autrev.2023.103330. View

Patzer R, McClellan W . Influence of race, ethnicity and socioeconomic status on kidney disease. Nat Rev Nephrol. 2012; 8(9):533-41. PMC: 3950900. DOI: 10.1038/nrneph.2012.117. View

Kang G, Jung K, Lee Y, Kim H, Yoon D, Lee S . Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea: a nationwide population-based study. Br J Dermatol. 2017; 178(1):e37-e39. DOI: 10.1111/bjd.15838. View

10.

Cozzi F, Marson P, Cardarelli S, Favaro M, Tison T, Tonello M . Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant. 2012; 27(12):4398-403. DOI: 10.1093/ndt/gfs317. View

11.

Reynolds K, Gu D, Muntner P, Chen J, Wu X, Yau C . Body mass index and risk of ESRD in China. Am J Kidney Dis. 2007; 50(5):754-64. DOI: 10.1053/j.ajkd.2007.08.011. View

12.

Steen V, Medsger Jr T, Osial Jr T, Ziegler G, Shapiro A, Rodnan G . Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984; 76(5):779-86. DOI: 10.1016/0002-9343(84)90986-0. View

13.

Shanmugam V, Steen V . Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012; 24(6):669-76. PMC: 4048657. DOI: 10.1097/BOR.0b013e3283588dcf. View

14.

Kim J, Yoon S, Kim L, Kim D . Towards Actualizing the Value Potential of Korea Health Insurance Review and Assessment (HIRA) Data as a Resource for Health Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of HIRA Data. J Korean Med Sci. 2017; 32(5):718-728. PMC: 5383602. DOI: 10.3346/jkms.2017.32.5.718. View

15.

Lin C, Su Y, Cheng T, Wu C, Chen J, Yu S . Increased risk of end-stage renal disease in patients with systemic sclerosis. Scand J Rheumatol. 2021; 51(2):120-127. DOI: 10.1080/03009742.2021.1917143. View

16.

Kwon O, Kim Y, Chun J, Han K, Park M, Kim R . Association of immune-mediated inflammatory diseases with depression and anxiety in patients with type 2 diabetes: A nationwide population-based study. Front Med (Lausanne). 2023; 10:1103911. PMC: 10150640. DOI: 10.3389/fmed.2023.1103911. View

17.

Pope J, Denton C, Johnson S, Fernandez-Codina A, Hudson M, Nevskaya T . State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023; 19(4):212-226. PMC: 9970138. DOI: 10.1038/s41584-023-00909-5. View

18.

Kwon O, Han K, Chun J, Kim R, Hong S, Kim J . Effects of immune-mediated inflammatory diseases on cardiovascular diseases in patients with type 2 diabetes: a nationwide population-based study. Sci Rep. 2022; 12(1):11548. PMC: 9262934. DOI: 10.1038/s41598-022-15436-8. View

19.

Volkmann E, Andreasson K, Smith V . Systemic sclerosis. Lancet. 2022; 401(10373):304-318. PMC: 9892343. DOI: 10.1016/S0140-6736(22)01692-0. View

20.

Zhang X, Fang Y, Zou Z, Hong P, Zhuo Y, Xu Y . Risk Factors for Progression of CKD with and without Diabetes. J Diabetes Res. 2022; 2022:9613062. PMC: 9424021. DOI: 10.1155/2022/9613062. View